Clinical trials: Schizo-Affective Type of Psychosis
Smoking Cessation
Novel Smoking Cessation Drug for Schizophrenia
The investigators will evaluate effects of a novel drug that improves nicotinergic receptor function vs. placebo on short-term smoking abstinence in smokers with schizophrenia who have a high interest in quitting.
- Trial name
- TRENDS (NCT02230384)
- Testing
- Active JNJ Drug
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- K.N. Roy Chengappa
Schizophrenia, Schizoaffective Disorders
A Follow up Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to assess the long-term efficacy of Olanzapine Pamoate (OP) Depot in patients diagnosed with schizophrenia or schizoaffective disorder.
- Trial name
- NCT01389908
- Testing
- olanzapine
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Shalvata Mental Health Center
Schizophrenia, Schizoaffective Disorder
Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia
Primary Objective: To test the effect of pramlintide on body weight in clozapine- and olanzapine-induced weight gain in persons with schizophrenia who are currently taking either drug; measures of the metabolic syndrome will be…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
- Trial name
- NCT00690235
- Testing
- Pramlintide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Texas Southwestern Medical Center
Schizophenia Disorder, Schizoaffective Disorder
Exercise and Olanzapine-samidorphan
This is a single site trial in 30 patients with schizophrenia, schizoaffective, or bipolar I/II/NOS disorder in which all participants will receive eight weeks of olanzapine and samidorphan (Olz/Sam) plus four weeks of aerobic…
- Conditions
- Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder I or II, Bipolar Disorder NOS
- Trial name
- NCT06740890
- Testing
- Olanzapine-samidorphan + exercise
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
The Effects of Rimonabant, on Weight and Metabolic Risk Factors
1) To examine the efficacy of rimonabant in decreasing weight and metabolic parameters/cardiovascular disease risk in people with schizophrenia receiving second generation antipsychotics 2) To examine the safety and tolerability…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Obesity, Hypertension
- Trial name
- NCT00547118
- Testing
- Rimonabant
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizoaffective Disorder
SUCCEED Africa: Support, Comprehensive Care and Empowerment of People With Psychosocial Disabilities
Although psychotic disorders typically affect less than 1% of the population, they are a significant cause of disability worldwide.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizotypal Disorder, Acute and Transient Psychotic Disorder
- Trial name
- SUCCEED (NCT06007105)
- Testing
- SUCCEED Community-Based Intervention
- Where
- 4 sites in Malawi, Nigeria and 2 more
- Volunteers
- 425 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Schizophenia Disorder, Severe Mental Illness
Effect of Occupational Therapy on Psychosocial Parameters and Functioning in Individuals With Severe Mental Illness
Severe mental illness (SMI), including schizophrenia spectrum disorders and bipolar disorder, is associated with significant impairments in psychosocial functioning, daily life participation, self-efficacy, and social…
- Conditions
- Schizophenia Disorder, Severe Mental Illness, Bipolar Disorder, Nonorganic Psychosis
- Trial name
- OT-SMI (NCT07879118)
- Testing
- Occupational Therapy Group Intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Biruni University
Schizophrenia, Schizoaffective Disorder
Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence
As many as 75 percent of patients with schizophrenia have difficulty taking their oral medication on a regular basis. This may lead to worsening of symptoms.
- Trial name
- NCT00215579
- Testing
- Depot Risperidone Microsphere (Consta)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Duke University
Schizophrenia, Schizoaffective Disorder
Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder
The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine. A secondary objective is to evaluate the safety and tolerability of 3 formulations of olanzapine.
- Trial name
- NCT06319170
- Testing
- Olanzapine Extended Release, Olanzapine Immediate Release
- Where
- 5 sites in United States
- Volunteers
- 106 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Patient Noncompliance
Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic
Psychotropic medications are a cornerstone of treatment for individuals with schizophrenia and schizoaffective disorder, however rates of full or partial non-adherence can exceed 60%.
- Trial name
- CAE-L (NCT01152697)
- Testing
- haloperidol decanoate, haloperidol, Customized Adherence Enhancement
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University Hospitals Cleveland Medical Center
Schizophrenia, Schizoaffective Disorders
Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia
This study involves people with schizophrenia or schizoaffective disorder, who are currently taking antipsychotic medications. Some antipsychotic medications may cause an increase in cholesterol levels, which may lead to…
- Conditions
- Schizophrenia, Schizoaffective Disorders, Schizophreniform Disorders
- Trial name
- NCT01082588
- Testing
- Pravastatin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizoaffective Disorder
Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic Patients
The purpose of this study was to evaluate the safety of risperidone treatment in acute psychotic patients that require an admission into emergency department.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- NCT00515489
- Testing
- Risperidone
- Volunteers
- 1,882 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia, Psychotic Disorders
Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
This study will assess the effectiveness of pimozide in enhancing the effects of clozapine in the treatment of schizophrenia.
- Trial name
- NCT00158223
- Testing
- Pimozide
- Where
- 3 sites in United States
- Volunteers
- 76 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Severe Mental Illness, Schizophrenia
The Potential Efficacy of the Chinese Health Improvement Profile- A Pilot Clustered Randomised Controlled Trial
The investigators programme of research will evaluate an existing physical health care screening intervention with the aim of helping Community Psychiatric Nurses (CPN) to improve the physical health wellbeing of people with a…
- Conditions
- Severe Mental Illness, Schizophrenia, Schizoaffective Disorder, Bipolar Affective Disorder
- Trial name
- CHIP (NCT02453217)
- Testing
- Chinese CHIP, Treatment as usual
- Volunteers
- 144 people
- Sponsor
- Wai-Tong Chien
Body Weight Change, Schizophrenia
Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
The primary purpose of this study is to compare the affects of aripiprazole and olanzapine on weight change.
- Conditions
- Body Weight Change, Schizophrenia, Schizoaffective Disorder, Psychotic Disorder
- Trial name
- NCT00095524
- Testing
- Aripiprazole
- Where
- 32 sites in United States, Brazil and 1 more
- Volunteers
- 300 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tobacco-Use Disorder, Schizophrenia
Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke
Many individuals with schizophrenia smoke cigarettes. Individuals in the schizophrenic population often find it difficult to quit smoking.
- Conditions
- Tobacco-Use Disorder, Schizophrenia, Psychotic Disorders
- Trial name
- NCT00307203
- Testing
- bupropion SR, Cognitive Behavioral Group Therapy, nicotine replacement therapy
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Schizophrenia, Schizoaffective Disorder
Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder
The proposed study is a 4-site, 12-week, novel, feasibility, investigation of patients who have co-occurring diagnoses of schizophrenia and current substance use disorder (alcohol, cocaine, heroin, or cannabis).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Substance Use Disorders
- Trial name
- NCT03526354
- Testing
- Brexpiprazole, Treatment as Usual
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Massachusetts, Worcester
Schizophrenia
A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia
This is a Phase 1, open-label study to evaluate the safety and pharmacokinetics (PK) of three doses of risperidone-SABER, administered with a needle and syringe or via the DosePro Needle-Free Delivery System in patients with…
- Trial name
- NCT01592110
- Testing
- risperidone-SABER, ZX003:risperidone-SABER and the DosePro System
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Zogenix, Inc.
Schizophrenia, Schizoaffective Disorder
Cognitive Remediation and Functional Skills Training in Schizophrenia
This randomized trial is examining whether a treatment called cognitive remediation is more effective when it is paired with a social and functional skills training component.
- Trial name
- NCT01175642
- Testing
- Cognitive Remediation, FAST
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- National Alliance for Research on Schizophrenia and Depression
Schizophrenia, Schizo Affective Disorder
Models of Auditory Hallucination
The purpose of this study is to address the shortcoming in clinical hallucination research by causally manipulating the neural loci of conditioned hallucination task behavior in-person in patients with psychosis using…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Auditory Hallucination
- Trial name
- NCT04210557
- Testing
- Transcranial Magnetic Stimulation (TMS)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Yale University